| Safety and Immunogenicity Study of a Liquid Pentavalent Combination Vaccine (NCT00617812) | Shantha Biotechnics Limited | 2008-03-01 |
| Phase IV Interchangeability Study of a Liquid Pentavalent Combination Vaccine (NCT00674908) | Shantha Biotechnics Limited | 2008-03-01 |
| Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children (NCT00611559) | GlaxoSmithKline | 2008-02-14 |
| Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine (NCT00635128) | GlaxoSmithKline | 2008-02-01 |
| Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine (NCT00627458) | GlaxoSmithKline | 2008-02-01 |
| Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination. (NCT00610168) | GlaxoSmithKline | 2008-01-01 |
| Study of Immunogenicity and Safety of a Booster Dose of DTaP-IPV-HB-PRP~T Combined Vaccine in Healthy Turkish Infants (NCT00619502) | Sanofi Pasteur, a Sanofi Company | 2007-12-01 |
| Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination in Study NCT01267058 (NCT00548171) | GlaxoSmithKline | 2007-11-05 |
| Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino Infants (NCT00514709) | Sanofi Pasteur, a Sanofi Company | 2007-09-01 |
| Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™ (NCT00534833) | Sanofi Pasteur, a Sanofi Company | 2007-09-01 |
| Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9 (NCT00489970) | GlaxoSmithKline | 2007-06-01 |
| Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines (NCT00463437) | GlaxoSmithKline | 2007-04-25 |
| Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio Vaccine (NCT00514059) | Norwegian Institute of Public Health | 2007-04-01 |
| Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age (NCT00467519) | Sanofi Pasteur, a Sanofi Company | 2007-04-01 |
| Study to Assess Safety & Immunogenicity of GSK Biologicals' Boostrix (dTpa) Vaccine vs. Chinese DT Vaccine (NCT00452686) | GlaxoSmithKline | 2007-03-01 |
| Seroimmunity 2007 and Sub Study of the Swedish Population Regarding Vaccine Preventable Disease (NCT00932269) | Swedish Institute for Infectious Disease Control | 2007-03-01 |
| A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older (NCT00457249) | Sanofi | 2007-03-01 |
| Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 Months (NCT00453570) | Sanofi | 2007-03-01 |
| REVAXIS® Versus DT Polio® as a Second Booster in 6 Year-old Children (NCT00447525) | Sanofi Pasteur, a Sanofi Company | 2007-02-01 |
| Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035) (NCT00432042) | Merck Sharp & Dohme LLC | 2007-01-12 |
| Study to Assess the Safety & Reactogenicity of GSK Biologicals' dTpa Vaccine (Boostrix) When Given at 6-8 Years of Age. (NCT00406562) | GlaxoSmithKline | 2007-01-01 |
| Lot Consistency Study of DTaP-IPV-HB-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy Infants (NCT00404651) | Sanofi Pasteur, a Sanofi Company | 2006-11-01 |
| Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults (NCT00385255) | GlaxoSmithKline | 2006-10-23 |
| Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age (NCT00376779) | GlaxoSmithKline | 2006-10-01 |
| Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL® (NCT00355121) | Sanofi | 2006-10-01 |
| Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai Infants (NCT00401531) | Sanofi Pasteur, a Sanofi Company | 2006-10-01 |
| Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Months of Age (NCT00379977) | GlaxoSmithKline | 2006-09-01 |
| Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPV (NCT00362336) | Sanofi Pasteur, a Sanofi Company | 2006-08-01 |
| Comparison of DTaP-HB-PRP~T Combined Vaccine to Tritanrix-HepB/Hib™, Both Given Concomitantly With Oral Polio Vaccine (NCT00343889) | Sanofi Pasteur, a Sanofi Company | 2006-08-01 |
| Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar® (NCT00362427) | Sanofi Pasteur, a Sanofi Company | 2006-08-01 |
| Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine (NCT00347958) | Sanofi Pasteur, a Sanofi Company | 2006-08-01 |
| Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years (NCT00346073) | GlaxoSmithKline | 2006-07-13 |
| Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2-3-4 Months Schedule (NCT00315055) | Sanofi Pasteur, a Sanofi Company | 2006-07-01 |
| Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers (NCT00343421) | Sanofi Pasteur, a Sanofi Company | 2006-07-01 |
| Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months. (NCT00313911) | Sanofi Pasteur, a Sanofi Company | 2006-07-01 |
| Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hib™, Concomitantly With OPV in Healthy Infants (NCT00348881) | Sanofi Pasteur, a Sanofi Company | 2006-06-01 |
| Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED) (NCT00337428) | Merck Sharp & Dohme LLC | 2006-05-01 |
| Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX® (NCT00319553) | Sanofi | 2006-05-01 |
| Immunogenicity and Safety of Tetraxim Versus Local DTP + IPV (NCT00319852) | Sanofi | 2006-04-01 |
| Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Given in Healthy Infants (NCT00320463) | GlaxoSmithKline | 2006-04-01 |
| Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025) (NCT00325130) | Merck Sharp & Dohme LLC | 2006-04-01 |
| Post-marketing Safety Study of GSK Biologicals' Boostrix® Vaccine (NCT00297856) | GlaxoSmithKline | 2006-03-01 |
| Immuno & Safety Study With 2 Formulations of DTPw-HBV/HIB When Given at Birth With Hepatitis B at 2, 4 and 6 Mths.Age. (NCT00316680) | GlaxoSmithKline | 2006-03-01 |
| Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine (NCT00304265) | Sanofi Pasteur, a Sanofi Company | 2006-03-01 |
| Lot-to-lot Consistency of Tritanrix™-HepB/Hib-MenAC & Its Non-inferiority vs Tritanrix™-HepB/Hiberix™ in Infants (NCT00197275) | GlaxoSmithKline | 2006-02-01 |
| Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants (NCT00287092) | Sanofi Pasteur, a Sanofi Company | 2006-02-01 |
| Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean Infants (NCT00303316) | Sanofi | 2006-02-01 |
| Immunogenicity and Safety of Pentaxim™ in an Indian Population (NCT00259337) | Sanofi | 2006-02-01 |
| US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease (NCT00282295) | GlaxoSmithKline | 2006-01-25 |
| Evaluation of the Immunogenicity, Safety and Reactogenicity of the Combined DTPa-IPV Vaccine in Healthy Infants (NCT00290342) | GlaxoSmithKline | 2006-01-01 |
| Immunology of Non-specific Effects of Vaccine (NCT00168545) | Bandim Health Project | 2006-01-01 |
| Pentavalent DTaP-Hep B-IPV (NCT00133445) | National Institute of Allergy and Infectious Diseases (NIAID) | 2005-12-01 |
| Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand (NCT00255021) | Sanofi | 2005-12-01 |
| Immunogenicity & Safety of GSK's Combined DTPa-HBV-IPV/Hib Vaccine in Indian Infants at 2 Diff Vaccination Schedules (NCT00316147) | GlaxoSmithKline | 2005-12-01 |
| Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488 (NCT00307567) | GlaxoSmithKline | 2005-11-01 |
| Safety and Immune Response of Different Pediatric Combination Vaccines. (NCT00255047) | Sanofi Pasteur, a Sanofi Company | 2005-11-01 |
| Immunogenicity and Safety of ADACEL™ as Fifth Dose in Taiwan (NCT00258908) | Sanofi Pasteur, a Sanofi Company | 2005-11-01 |
| Immunogenicity and Safety of Pentaxim in South African Infants (NCT00254969) | Sanofi | 2005-10-01 |
| Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in Children (NCT00228917) | GlaxoSmithKline | 2005-06-16 |
| Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine (NCT00777257) | Sanofi Pasteur, a Sanofi Company | 2005-04-01 |
| Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL® (NCT00258895) | Sanofi Pasteur, a Sanofi Company | 2005-03-01 |
| Immune Memory of DTPw-HBV/Hib Vaccine Following Primary Vaccination, Immuno & Reacto of a Booster Dose Given in Infants (NCT00169442) | GlaxoSmithKline | 2005-02-10 |
| Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines (NCT00148941) | GlaxoSmithKline | 2005-01-06 |
| Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants (NCT00325156) | GlaxoSmithKline | 2004-11-02 |
| Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants (NCT00831311) | Sanofi Pasteur, a Sanofi Company | 2004-10-01 |
| Assessment of the Reactogenicity of ADACEL® (TdcP Vaccine) in Children and Adolescents 7 to 19 Years of Age (NCT00524732) | Sanofi Pasteur, a Sanofi Company | 2004-09-01 |
| Immunogenicity & Safety Study of a Vaccine Against Meningitis in Infants (2,4,6 Months) After a Hepatitis B Birth Dose. (NCT00317161) | GlaxoSmithKline | 2004-08-01 |
| Safety Study of a Vaccine Against Meningitis in Infants (2,4 & 6 Months Age) After a Birth Dose of Hepatitis B. (NCT00317187) | GlaxoSmithKline | 2004-06-08 |
| Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine Compared With U.S. Manufactured Td (NCT00601835) | Sanofi Pasteur, a Sanofi Company | 2004-05-01 |
| Assess if Immune Response of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Given Without or With Hepatitis B Vaccine at Birth is at Least as Good as Tritanrix™-HepB/Hiberix™ Without Hepatitis B Vaccine at Birth, When Given to Healthy Infants (NCT00290303) | GlaxoSmithKline | 2004-05-01 |
| Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ (NCT00802867) | Sanofi Pasteur, a Sanofi Company | 2004-02-01 |
| Safety Study of a Vaccine Against Meningitis in Infants ( 2,4 & 6 Months Age) After a Birth Dose of Hepatitis B. (NCT00317135) | GlaxoSmithKline | 2003-12-11 |
| Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B Vaccine (NCT00325143) | GlaxoSmithKline | 2003-12-01 |
| Assessment of GSK Biologicals' Tdap Candidate Vaccine Administered as a Booster (6th Dose) in Terms of Immunogenicity and Safety to Children and Adolescents Previously Vaccinated With Five Doses of an Acellular Pertussis-containing Vaccine. (NCT00263679) | GlaxoSmithKline | 2003-11-01 |
| Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination Course (NCT01457547) | GlaxoSmithKline | 2003-10-01 |
| Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines (NCT00254917) | Sanofi | 2003-10-01 |
| Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™ (NCT00772928) | Sanofi | 2003-10-01 |
| Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age). (NCT00352963) | GlaxoSmithKline | 2003-09-30 |
| Retrospective Survey of Safety of Fourth Dose Pentacel® in Children (NCT00772369) | Sanofi Pasteur, a Sanofi Company | 2003-09-01 |
| Post Market Surveillance for Infanrix™ (NCT00908115) | GlaxoSmithKline | 2003-08-01 |
| A Study to Assess Antibody Persistence, Boostability & Safety in Previously Primed Subjects. (NCT00317174) | GlaxoSmithKline | 2003-07-01 |
| Immunogenicity, Antibody Persistence and Safety of GSK Biologicals' DTPa (INFANRIX) and dTpa (BOOSTRIX) Vaccines. (NCT00544271) | GlaxoSmithKline | 2003-05-01 |
| Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV) (NCT01294605) | GlaxoSmithKline | 2003-04-01 |
| Post-marketing Safety Study of GSK Biological's Pediarix™ Vaccine (NCT00146835) | GlaxoSmithKline | 2003-04-01 |
| A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine (NCT00109330) | GlaxoSmithKline | 2002-11-01 |
| Assess Immune Response Following Primary Vaccination With Tritanrix™-HepB Vaccine Mixed With 3 Formulations of Hib-MenAC Vaccine to Infants (NCT00291967) | GlaxoSmithKline | 2002-11-01 |
| Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in Terms of Immune Response and Safety (NCT00263692) | GlaxoSmithKline | 2002-11-01 |
| Study of an Investigational Vaccine in Healthy Infants in Taiwan (V441-001)(COMPLETED) (NCT00092469) | Merck Sharp & Dohme LLC | 2002-03-01 |
| Comparison of GSK Biologicals' Reduced Antigen Diphtheria and Tetanus Toxoids and Acellular Pertussis- Inactivated Poliovirus Vaccine, to BoostrixTM and Inactivated Poliovirus Vaccine Administered Separately and With Revaxis® (NCT01277705) | GlaxoSmithKline | 2002-01-01 |
| Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine (NCT00662870) | Sanofi | 2001-05-01 |
| Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants (NCT00879827) | GlaxoSmithKline | 2000-09-01 |
| Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio Vaccine (NCT01457560) | GlaxoSmithKline | 2000-02-01 |
| Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib, Compared to DTPa-HBV-IPV and Hib Administered Separately (NCT01457508) | GlaxoSmithKline | 1999-01-01 |
| Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly (NCT01457495) | GlaxoSmithKline | 1998-09-01 |
| Booster Study of Combined Diphtheria-tetanus-acellular Pertussis Vaccine in Healthy Adults (NCT01267058) | GlaxoSmithKline | 1997-09-01 |
| Pilot Study Freeze and Transport Immune Cells (NCT00138268) | National Institute of Allergy and Infectious Diseases (NIAID) | |